A Proof-of-Concept Trial to EvaluAte the EfficaCy and Safety Of Cell Therapy TRX103 Administered Intravenously in Patients With Active, Non-infectious Intermediate, Posterior, and Pan-Uveitis - PEACOCX Study

Inclusion Criteria: 1. ≥ 18 to ≤ 70 years of age at time of consent. 2. Weight of ≥ 40 kg at time of consent. 3. Subjects must be able to understand and sign informed consent and be willing and able to complete all specified procedures and visits. 4. Diagnosis of active non-infectious uveitis (NIU); intermediate, posterior, or panuveitis at screening as defined as having at least ONE of the following findings: 1. .≥ 2+ VH (NEI/SUN Scale) OR 2. Active inflammatory chorioretinal or inflammatory retinal lesion or lesions as defined by fluorescein angiography (FA) or optical coherence tomo…